Browne L Daniel 4
4 · Revance Therapeutics, Inc. · Filed Mar 9, 2018
Insider Transaction Report
Form 4
Browne L Daniel
DirectorCEO and President
Transactions
- Sale
Common Stock
2018-03-07$31.43/sh−27,283$857,505→ 131,208 total
Holdings
- 409(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.85. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.